Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29489190 | 1.00 | LMNA (0.38) | LMNASMN1; SMN2GAAMAPTBRD4 | |
| Hydrochloric Acid SCHEMBL29197876 | 0.98 | LMNA (0.38) | LMNASMN1; SMN2GAAMAPTBRD4 | |
| Hydrochloric Acid SCHEMBL30920862 | 0.98 | LMNA (0.38) | LMNASMN1; SMN2GAAMAPTBRD4 | |
| SCHEMBL368056 | 0.83 | TSHR (0.36) | LMNAGAAMAPTMEN1ALOX15 | |
| SCHEMBL29655630 | 0.82 | P2RX4 (0.33) | GAAMAPTMEN1ALOX15CASP1 | |
| SCHEMBL13078687 | 0.80 | MAPT (0.40) | SMN1; SMN2GAAMAPT | |
| SCHEMBL7138274 | 0.74 | LMNA (0.39) | LMNASMN1; SMN2GAAMAPTBRD4 | |
| SCHEMBL4698118 | 0.70 | KDM4E (0.43) | LMNASMN1; SMN2GAAMAPTMEN1 | |
| SCHEMBL12159337 | 0.70 | GAA (0.44) | GAAMAPTBRD4CREBBPNOS2 | |
| SCHEMBL6056252 | 0.70 | GAA (0.44) | GAAMAPTBRD4CREBBPNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0070021-B1 | PROCESS FOR THE PREPARATION OF CYCLIC HEXAPEPTIDE | MERCK & CO. INC. (US) | 1986-01-08 | — | — | EP | claimed |
| US-20240277714-A1 | USE OF SOS1 INHIBITORS WITH RAS INHIBITORS TO TREAT CANCERS | Revolution Medicines, Inc. | 2024-08-22 | — | — | US | disclosed |
| CN-117957021-A | Process for preparing pegylated adrenomedullin, intermediates therefor and uses thereof | 拜耳公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-113292539-B | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2018140435-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2003024451-A1 | 2-(2-PHENYLETHYL)-BENZIMIDAZOLE-5-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRYPTASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-03-27 | — | — | WO | disclosed |
| EP-0624160-B1 | 2-ISOCEPHEM AND OXACEPHEM DERIVATIVES, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES THEREOF AND USE AS ANTIBACTERIAL AGENTS | PFIZER (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-0594263-B1 | INTERMEDIATES FOR THE PREPARATION OF THIOALKYLTHIO CEPHALOSPORIN DERIVATIVES | SHIONOGI & CO (JP) | 1999-06-09 | — | — | EP | disclosed |
| CN-1034504-C | Thioalkylthio cephalosporin derivatives | SHIONOGI & CO (JP) | 1997-04-09 | — | — | CN | disclosed |
| EP-0409164-B1 | Phenacylpyridiniothiocephalosporins | SHIONOGI & CO (JP) | 1996-06-05 | — | — | EP | disclosed |
| EP-0117143-A2 | Cephalosporin hydroxamic acids, their preparation, antibacterial formulations comprising the same, and their use in combating bacteria | SHIONOGI & CO., LTD. (JP) | 1984-08-29 | — | — | EP | disclosed |
| WO-1984002911-A1 | beta-LACTAM ANTIBACTERIAL AGENTS | BEECHAM GROUP PLC (GB) | 1984-08-02 | — | — | WO | disclosed |
| EP-0114750-A2 | Beta-lactam antibacterial agents | BEECHAM GROUP PLC (GB) | 1984-08-01 | — | — | EP | disclosed |
| EP-0107928-A1 | Vinylthioacetamido oxacephalosporin derivatives, and intermediates therefor, their preparation, formulations containing the same and their antibacterial use | SHIONOGI & CO., LTD. (JP) | 1984-05-09 | — | — | EP | disclosed |
| EP-0071395-A1 | Beta-lactam antibacterial agents | BEECHAM GROUP PLC (GB) | 1983-02-09 | — | — | EP | disclosed |
| US-4269773-A | CEPHALOSPORINS | SHIONOGI & CO., LTD. (JP) | 1981-05-26 | — | — | US | disclosed |
| US-4232151-A | ANTIBIOTICS | SHIONOGI & CO., LTD. (JP) | 1980-11-04 | — | — | US | disclosed |
| US-4201782-A | BACTERICIDES | SHIONOGI & CO., LTD. (JP) | 1980-05-06 | — | — | US | disclosed |
| US-4183928-A | Haloarylmalonamidooxacephalosporins | SHIONOGI AND CO., LTD. (JP) | 1980-01-15 | — | — | US | disclosed |
| US-4159984-A | METAL AND PROTON DONOR | SHIONOGI & CO., LTD. (JP) | 1979-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277714-A1 | USE OF SOS1 INHIBITORS WITH RAS INHIBITORS TO TREAT CANCERS | SOS1, HRAS, KRAS | LMNA 4283/4885SMN1; SMN2 1420/4885GAA 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.